SCHEMBL5310771

SCHEMBL5310771

c1ccc(-n2ncc3cnc4ccccc4c32)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 1/20 0.50
GRM4 Q14833 3/20 0.49
KDM4E B2RXH2 4/20 0.48
GPR3 P46089 1/20 0.48
PLA2G10 O15496 1/20 0.43
NPC1 O15118 4/20 0.43
RAB9A P51151 4/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
LMNA P02545 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
GLA P06280 1/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
CA9 Q16790 2/20 0.42
ALDH1A1 P00352 2/20 0.41
HSD17B10 Q99714 2/20 0.41
EGFR P00533 1/20 0.41
CYP1A2 P05177 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31399060 0.77 GPR3 (0.50) ADORA3GRM4KDM4EGPR3LMNA
SCHEMBL31399065 0.73 KDM4E (0.46) ADORA3GRM4KDM4EGPR3CYP1A2
SCHEMBL28406052 0.72 ALDH1A1 (0.46) ADORA3GRM4KDM4EGPR3NPC1
SCHEMBL29703258 0.71 RAB9A (0.76) KDM4EPLA2G10NPC1RAB9ASMN1; SMN2
SCHEMBL4238032 0.71 RAB9A (0.76) KDM4EPLA2G10NPC1RAB9ASMN1; SMN2
SCHEMBL25257898 0.71 PLA2G10 (0.46) KDM4EPLA2G10NPC1RAB9ASMN1; SMN2
SCHEMBL29405456 0.71 PLA2G10 (0.46) KDM4EPLA2G10NPC1RAB9ASMN1; SMN2
SCHEMBL9395199 0.70 ADORA3 (0.55) ADORA3GRM4KDM4EGPR3NPC1
Hydrochloric Acid SCHEMBL30088977 0.70 RAB9A (0.73) KDM4EPLA2G10NPC1RAB9ASMN1; SMN2
SCHEMBL2252071 0.69 FGFR1 (0.54) ADORA3RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4416146-A1 SUBSTITUTED 1H-PYRAZOLO [4,3-C] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF Lomond Therapeutics, Inc. (US) 2024-08-21 EP claimed
WO-2023064133-A1 SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF LOMOND THERAPEUTICS, INC. (US) 2023-04-20 WO claimed
US-20250011319-A1 SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF LOMOND THERAPEUTICS, INC. 2025-01-09 US disclosed
CN-118076605-A Substituted 1H-pyrazolo [4,3-c ] quinolines, methods of preparation and uses thereof 洛蒙治疗公司 2024-05-24 CN disclosed
EP-1427706-B1 SUBSTITUTED PYRAZOLO COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORP (US) 2007-05-30 EP disclosed
US-7211597-B2 Substituted pyrazolyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2007-05-01 US disclosed
EP-1427706-A1 SUBSTITUTED PYRAZOLO COMPOUNDS FOR THE TREATMENT OF INFLAMMATION Pharmacia Corporation (US) 2004-06-16 EP disclosed
US-20030114432-A1 Substituted pyrazolyl compounds for the treatment of inflammation PHARMACIA CORPORATION 2003-06-19 US disclosed
WO-2003024936-A1 SUBSTITUTED PYRAZOLO COMPOUNDS FOR THE TREATMENT OF INFLAMMATION PHARMACIA CORPORATION (US) 2003-03-27 WO disclosed
US-5886016-A ANTIINFLAMMATORY AGENT WITH MINIMAL SIDE EFFECTS FOR TREATING ARTHRITIS G.D. SEARLE & CO. (US) 1999-03-23 US disclosed
US-5670532-A Pyrazolyl derivatives for the treatment of inflammation G. D. SEARLE & CO. (US) 1997-09-23 US disclosed
US-5565482-A ANTIINFLAMMATORY AGENTS, ANTIARTHRITIC AGENTS G.D. SEARLE & CO. (US) 1996-10-15 US disclosed
US-5547975-A ANTIARTHRIC AGENTS, ANALGESICS AND ANTIPYRETICS; INHIBITORS OF CYCLOOXYGENASE II; SIDE EFFECT REDUCTION G.D. SEARLE & CO. 1996-08-20 US disclosed
WO-1996009304-A1 BENZOPYRANOPYRAZOLYL DERIVATIVES FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114432-A1 Substituted pyrazolyl compounds for the treatment of inflammation IRAK4, IL1B, IRAK2 ADORA3 1834/4885GRM4 1722/4885KDM4E 2282/4885
US-20250011319-A1 SUBSTITUTED 1H-PYRAZOLO [4,3-c] QUINOLINES, METHODS OF PREPARATION, AND USE THEREOF FLT3, PDXK, PHKG1 ADORA3 3003/4885GRM4 2324/4885KDM4E 2039/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.